This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.

Original Research

Evaluation of Hepatitis C Screening and Treatment Among Psychiatry Inpatients

Erin Mandel, MPH; Mia J. Biondi, NP, PhD; Andrew Mendlowitz, PhD; Margaret Maheandiran, MSc; Elizabeth Hollingdrake, MA; Aaron Vanderhoff, BS; Brett Wolfson-Stofko, PhD; Camelia Capraru, MD; Jordan J. Feld, MD, MPH; and Renee Logan, MD

Published: July 31, 2023

ABSTRACT

Objective: To evaluate uptake of hepatitis C virus (HCV) testing and treatment among psychiatry inpatients at Canada’s largest mental health institution, the Centre for Addiction and Mental Health (CAMH).

Methods: We reviewed medical records for all forensic and long-stay mental health patients from January 2017 to May 2021 to examine rates of HCV testing (antibody and RNA), treatment, and follow-up and completed a logistical regression to identify predictors associated with HCV antibody (Ab) screening among inpatients.

Results: Of 1,031 patients, 73% (n = 753) were male, mean age was 44 years (range: 20–92), and mean length of stay was 7.1 months (range: 0 days–24 years). Most, 83% (n = 856), were diagnosed with schizophrenia spectrum disorders. In total, 652/1,031 (63%) of individuals in this cohort received HCV Ab screening. When broken down by admission rather than individual, 570/1,303 (44%) forensic admissions had an associated HCV Ab screening, and 318/1,450 (22%) non-forensic admissions had an associated HCV Ab screening. Individuals admitted to a forensic unit and those diagnosed with schizophrenia or substance use disorders were more likely to undergo HCV Ab screening, while individuals of Asian ethnicity were less likely (all P < .05). HCV Ab positivity was 4.9%, and most (84%, n = 27) HCV Ab–positive individuals had subsequent RNA testing, of whom 56% (n = 15) tested HCV RNA positive. Of 15 RNA-positive individuals, 10 initiated treatments, 7 on-site at CAMH and 3 at a local hepatology center. A total of 7 individuals (1 treated by specialists and 6 on-site) achieved sustained virological response or cure. The remaining 3 were lost to follow-up, 2 of whom were treated at the hepatology clinic.

Conclusions: Based on the high prevalence of HCV, mental health inpatients should be included in groups for whom universal screening is recommended. Since on-site treatment was more successful than referral to external hepatology specialists, utilizing inpatient admission as an opportunity for HCV screening and treatment should receive more consideration.

J Clin Psychiatry 2023;84(5):22m14623

Author affiliations are listed at the end of this article.

Volume: 84

Quick Links: Hepatitis

Continue Reading…

Subscribe to read the entire article

$40.00

Buy this Article as a PDF

References